Teledentistry and the Distant Diagnosis of Oral Mucosal Disease

2014 ◽  
pp. 13-21 ◽  
Author(s):  
Cassius C. Torres-Pereira ◽  
Imara de Almeida Castro Morosini ◽  
Bruna Basso Fonseca
Keyword(s):  
Mucosal Disease

Impfung gegen BVD/MD: direkter Vergleich verschiedener Impfstoffe und Impfregime

2006 ◽  
Vol 34 (05) ◽  
pp. 281-288
Author(s):  
L. Jöns-Anders ◽  
Ch. Förster ◽  
K. Fading ◽  
H.-P. Heckert ◽  
H.-J. Thiel ◽  
...  
Keyword(s):  
Klinische Relevanz ◽  
Mucosal Disease

Zusammenfassung: Gegenstand und Ziel: Die bovine Virusdiarrhö/Mucosal Disease( BVD/MD) stellt nach wievor eine der ökonomisch bedeutsamsten Virusinfektionen des Rindes dar. Aufgrund der hohen Prävalenz des Erregers und der geographischen Lage ist der Einsatzvon Impfstoffen bei der Bekämpfung der BVD/MD in Deutschland nach verbreiteter Ansicht derzeit unverzichtbar. Zentrale Bedeutung besitzt dabei der Schutz vor diapla- zentarer Übertragung des Virus. Eine Reihe von Impfstoffen gegen BVD/MD auf der Basis von vermehrungsfähigem Virus (“Lebendvakzinen”) bzw. inaktiviertem Virus (“Totvakzinen”) ist derzeit in Deutschland zugelassen, zum Teil mit dem Zusatz “fetaler Schutz”. Neben dem alleinigen Einsatz von “Lebend-” bzw. “Totvakzinen” werden beide Impfstoffarten auch kombiniert im Rahmen des so genannten zweistufigen Impfregimes verwendet. Ziel der vorliegenden Untersuchung war der Vergleich unterschiedlicher Impfstoffe und Impfregime. Material und Methoden: In einem Tierversuch wurden 60 Rinder mit unterschiedlichen Impfstoffen gegen BVD/MD immunisiert. Über einen Zeitraum von 10 Monaten wurden Serumproben der Tiere gewonnen und im Neutralisationstest gegen drei BVD-Testviren aus den Gruppen BVDV-1a,-1b und BVDV-2a getestet. Ergebnisse: Die zweimalige Immunisierung mit dem neuen Impfstoff PregSure® BVD ergab vergleichbar hohe neutralisierende Antikörpertiter gegen BVDV-1 wie die Kombination von “Totimpfstoff” und “Lebendimpfstoff” im zweistufigen Verfahren. Hinsichtlich BVDV-2führte die zweimalige Impfung mit PregSure® BVD sogar zu höheren Titern. Schlussfolgerungen: Es zeigte sich,dass der neue “Totimpfstoff” PregSure® BVD auchfürden Einsatz im Rahmen zweistufiger Impfprogramme gut geeignet ist. Klinische Relevanz: Der alleinige Einsatz von “Totimpfstoffen” bietet praktische Vorteile. Wichtigstes Ziel aller Impfungen gegen BVD/MD bleibt der “fetale Schutz”.

Bovine viral diarrhea virus genomic associations in mucosal disease, enteritis and generalized dermatitis outbreaks in Argentina

2003 ◽  
Vol 96 (2) ◽  
pp. 133-144 ◽  
Author(s):  
Anselmo C Odeón ◽  
Guillermo Risatti ◽  
Germán G Kaiser ◽  
Marı́a R Leunda ◽  
Ernesto Odriozola ◽  
...  
Keyword(s):  
Bovine Viral Diarrhea Virus ◽  
Bovine Viral Diarrhea ◽  
Diarrhea Virus ◽  
Viral Diarrhea ◽  
Mucosal Disease ◽  
Viral Diarrhea Virus

Pantoprazole-induced Thrombocytopenia: Unresponsive to Corticosteroid and Thrombocyte Concentrate Transfusion

2021 ◽  
pp. 089719002110647
Author(s):  
Widyati ◽  
Nurul Latifah ◽  
Maya Ramadhani
Keyword(s):  
Platelet Count ◽  
Prophylactic Therapy ◽  
Immune Mechanism ◽  
Drug Induced ◽  
Stress Ulcers ◽  
Present Case Report ◽  
Once Daily ◽  
Mucosal Disease ◽  
Critical Ill Patients ◽  
Critical Ill

Introduction Pantoprazole is a proton pump inhibitor (PPI) class drug that is widely used in the treatment of SRMD (stress-related mucosal disease in critical ill patients. PPI are one class of drugs used commonly both for treatment and prophylactic therapy for stress ulcers in intensive care unit (ICU). Case We report a case of a 51-year old male who was referred to PKU Hospital. He was admitted to ICU with diagnosis of Hyperosmolar Hyperglymic State and bronchopneumonia. Thrombocytopenia was noted in admission. There was more than 70% decrease in platelet count after initiation of pantoprazole. Patient received Thrombocyte Concentrate (TC) transfusion and corticosteroid iv for several days, but only had minor increase in platelet count. The platelets recovered after stopping pantoprazole. Discussion In the present case report, another exposures to parenteral pantoprazole in a dose of 40 mg once daily reproduced the same adverse drug reaction. In comparison to lansoprazole, thrombocytopenia from pantoprazole is more severe that necessitate TC transfusion and corticosteroid trial. However, in the present case, TC transfusion and corticosteroid fail to escalate platelet count. This finding suggests probability of non-immune mechanism of pantoprazole-induced thrombocytopenia. Conclusion Pantoprazole may induce thrombocytopenia with new features that were immediately developed, resulting a decrease in platelet count >70%. The mechanism found in this case may be non-immune. Drug-induced thrombocytopenia is one of the rare complications that has to be kept in mind with the use of pantoprazole.

scholarly journals Anemia and hematinic deficiencies in gastric parietal cell antibody-positive and -negative oral mucosal disease patients with microcytosis

2017 ◽  
Vol 116 (8) ◽  
pp. 613-619 ◽  
Author(s):  
Hung-Pin Lin ◽  
Yu-Hsueh Wu ◽  
Yi-Ping Wang ◽  
Yang-Che Wu ◽  
Julia Yu-Fong Chang ◽  
...  
Keyword(s):  
Parietal Cell ◽  
Gastric Parietal Cell ◽  
Mucosal Disease ◽  
Cell Antibody ◽  
Parietal Cell Antibody

Immunomodulating Effects of "Tien-Hsien Liquid" on Peripheral Blood Mononuclear Cells and T-Lymphocytes from Patients with Recurrent Aphthous Ulcerations

2004 ◽  
Vol 32 (02) ◽  
pp. 221-234 ◽  
Author(s):  
Andy Sun ◽  
Jean-San Chia ◽  
Won-Bo Wang ◽  
Chun-Pin Chiang
Keyword(s):  
T Cells ◽  
Peripheral Blood Mononuclear Cells ◽  
Peripheral Blood ◽  
Mononuclear Cells ◽  
Staphylococcal Enterotoxin B ◽  
Chinese Medicinal Herbs ◽  
Peripheral Blood Mononuclear ◽  
Mucosal Disease ◽  
Blood Mononuclear Cells ◽  
Proliferation Response

Recurrent aphthous ulcerations (RAU) represent a common oral mucosal disease with altered humoral and cellular immunities. In our institution, an immunomodulating agent, levamisole, is used to treat RAU with satisfactory therapeutic effect. Tien-Hsien liquid (THL) is an extract of Chinese medicinal herbs with immunomodulating effects. To test whether THL has immunomodulating effects on antigen-stimulated proliferation response (PR) of peripheral blood mononuclear cells (PBMC) and T-cells isolated from RAU patients and to test whether THL is a potential drug for treating RAU, PBMC or T-cells isolated from RAU patients were incubated with lipopolysaccharides (LPS) from Escherica coli, phytohemagglutinin (PHA), staphylococcal enterotoxin B (SEB), glutaraldehyde-inactivated tetanus toxoid (TT), glucosyltransferase D (GtfD), or antigens of Streptococcus mutans in the presence or absence of THL. We found that THL significantly increased the LPS-stimulated PR of PBMC from active RAU patients, the GtfD-stimulated PR of PBMC and of T-cells from inactive RAU patients, and the S. mutans-stimulated PR of PBMC from inactive RAU patients. However, THL could also significantly reduce the SEB-stimulated PR of PBMC and of T-cells from active RAU patients and S. mutans-stimulated PR of T-cells from active RAU patients. These results suggest that THL can modulate the antigen-stimulated PR of PBMC and T-cells from RAU patients. Therefore, it may be a potential immunoceutical agent for treatment of RAU.

Sign in / Sign up

Export Citation Format

Share Document